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Osteopontin (OPN) is one of the glycosylated
phosphoproteins produced in the kidney that can modulate
nephrolithiasis. We had previously found a modest
association between OPN gene polymorphisms and the risk
for urinary stone formation. In order to determine if
sequence variants within the OPN gene could be linked to
the risk of nephrolithiasis; we sequenced the entire OPN gene
of 45 stone forming patients and 54 control patients of
Japanese ancestry. We identified 61 polymorphisms and of
these evaluated four haplotype-tagging single nucleotide
polymorphisms in a total of 126 kidney stone cases and
214 healthy individuals; all of Japanese ancestry. There was
a significant association of two of these haplotypes
located in the OPN promoter with the relative probability
of nephrolithiasis; one of increased and one of reduced
risk. Our findings provide potential support for significant
increased and decreased associations between OPN gene
haplotypes and the relative potential of stone formation
in the Japanese population. We suggest that such genetic
findings may help to clarify the function of OPN in
nephrolithiasis.
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Nephrolithiasis is a complex multifactorial disease resulting
from an interaction between the environmental and genetic
factors. There may be as high as a 5–10% lifetime risk of
developing nephrolithiasis.1 When the kidney performs its
important function of conserving essential nutrients, elim-
inating waste products, and excreting salt and water in the
final urine, there is the risk of crystals formation owing to
tubular fluid supersaturated with calcium salts, and crystals
are frequently found, even in the healthy urinary tract. At the
same time, the kidney also generates numerous macromo-
lecular proteins, which have been isolated and identified in
both the urine and kidney stones matrix over the years.2–5
These proteins exist widely both in healthy individuals and in
those with nephrolithiasis and modulate crystal nucleation,
growth, aggregation and adhesion to renal epithelial cells, and
greatly affect the risk of forming nephrolithiasis.5–8 Complex
interactions between crystals and macromolecular proteins in
renal tubules play a key role in the pathogenesis of
nephrolithiasis. Stones may arise from abnormalities of
compromises in these interactions.
Osteopontin (OPN), a multifunctional glycosylated phos-
phoprotein, is a member of the SIBLING (small integrin-
binding ligand, N-linked glycoprotein) family. OPN was not
only identified as the main organic component in the urinary
stones matrix, but also had remarkably increased expression
in the distal tubular cells in the stone-forming rat.2,9 An
analysis of gene expression using microarray technology has
shown that the OPN gene was markedly upregulated in rats
during the development of calcium stone formation.10 Many
studies suggested the OPN was a natural inhibitor of
abnormal calcification in the kidneys of rats and has a vital
inhibitory role in the phases of stone formation, including
crystallization, crystal retention, crystal congregation, and
stone formation in vitro or in vivo.11–13 Other studies have
also shown that OPN plays a role in stimulating the
deposition and adhesion of crystals to cells in the early
stages of stone formation14 and calcium oxalate monohydrate
crystal coating with OPN correlated with increased adhesion
tendency.15 Whether it acts as an inhibitor or promoter of
kidney stone formation is still controversial.
Understanding the genetic basis of complex human
diseases has been increasingly emphasized as a means of
achieving insight into disease pathogenesis. A single nucleo-
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tide polymorphism (SNP) of the human OPN gene had been
reported to be associated with kidney stone risk using a
fluorescent 50endonuclease assay by our study group.16
Taking into consideration that the OPN gene is among
the most promising susceptibility genes for nephrolithiasis,
we resequenced the entire human genomic OPN gene in
nephrolithiasis cases and controls, searched haplotype-
tagging SNPs (htSNPs), and analyzed the association of
haplotypes with the risk of nephrolithiasis in this study.
RESULTS
Human OPN gene polymorphisms
Approximately 11 kb of the OPN gene was entirely rese-
quenced in 45 cases and 54 controls. A total of 61
polymorphism loci, including six novel polymorphisms,
were validated and detected. One SNP, rs5860110, was
removed from further statistical analysis because of deviation
from the Hardy–Weinberg equilibrium (Po0.001). Twenty-
three SNPs with minor allele frequencies X1% (Table 1),
including six novel SNPs, were used to test the allele
frequency differences and calculate the degree of linkage
disequilibrium (LD) (D0 and r2) between these pairs of SNP
loci. The position of the transcription start site was
designated as þ 1.
LD and haplotype analysis
Linkage analysis was performed for all possible pair-wise
combinations of 23 SNPs with minor allele frequenciesX1%.
Figure 1 shows a visual depiction of the degree of LD.
The value of the standard disequilibrium coefficient D0 is
used to assess the degree of LD. Four LD blocks were defined
and a total of 11 htSNPs were detected (Figure 1, Table 1).
Block 1, containing two htSNPs (rs2728127 and rs2853744)
located in the promoter of the OPN gene; block 2, containing
four htSNPs (novel 2, novel 3, rs2853749, and rs2853750)
spanning the proximal promoter and intron 1; block 3,
containing two htSNPs (novel 4 and novel 5) located in
intron 3; and block 4, containing three htSNPs (rs6532039,
rs4754, and rs1126616) located in a relative long region from
intron 3 to exon 7. Neighboring blocks showed strong LDs
toward each other. The genotypic distributions of the
haplotypes generated from htSNPs in each block did not
deviate from the Hardy–Weinberg equilibrium.
Association analysis
At first, we tested association of OPN gene polymorphisms
and haplotypes in four blocks with kidney stone risk between
45 cases and 54 controls. Two novel SNPs, novel 2 and novel
3, were revealed to have a significant allele frequency
difference between cases and controls (Po0.01) (Table 1).
In block 2, four htSNPs generated four main haplotypes and
significant differences of haplotype frequencies were detected
in haplotype T-G-T-G (odds ratio (OR)¼ 0.0526; 95%
confidence interval (CI): 0.007–0.402; P¼ 0.0001) and
haplotype G-T-T-G (OR¼ 3.7947; 95% CI: 1.31–10.989;
P¼ 0.0093) between cases and controls; whereas, there was
no statistically significant association of haplotype frequen-
cies in blocks 1, 3, and 4 (Table 2). Then, we further
genotyped the four htSNPs in block 2 in an additional 76
kidney-stone cases and 160 controls. A similar analysis was
Table 1 | Association analysis of 23 SNPs with minor allele frequencies greater than 1% between 45 cases and 54 controls
Alleles Case Control
No. refSNPID Position Location Major/minor (n=45) (n=54) OR 95% CI v2 P-value
2 rs2728127 1747 Promoter A/G 75/15 85/23 0.739 0.340–1.520 0.678 0.410
4 rs2853744 615 Promoter G/T 75/15 85/23 0.739 0.340–1.520 0.678 0.410
5 rs11730582 442 Promoter C/T 47/43 66/42 1.438 0.816–2.533 1.583 0.208
7 novel.1 301 Promoter A/C 86/04 104/04 1.209 0.294–4.978 0.069 0.792
10 novel.2 145 Promoter T/G 76/14 103/05 3.795 1.310–10.989 6.755 0.009**
11 novel.3 144 Promoter G/T 76/14 103/05 3.795 1.310–10.989 6.755 0.009**
19 rs2853749 953 Intron 1 C/T 75/15 82/26 0.631 0.311–1.281 1.641 0.200
20 rs2853750 1019 Intron 1 A/G 75/15 84/24 0.700 0.342–1.433 0.958 0.328
22 rs11728697 2079 Intron 3 C/T 42/48 60/48 1.429 0.815–2.505 1.553 0.213
25 novel.4 2557 Intron 3 T/A 70/20 82/26 0.901 0.464–1.751 0.094 0.759
26 novel.5 2571 Intron 3 A/T 65/25 80/28 1.099 0.585–2.065 0.086 0.770
27 rs6839524 2670 Intron 3 C/G 62/28 73/31 1.064 0.576–1.963 0.039 0.844
29 rs6840362 3056 Intron 3 C/T 86/04 103/05 0.958 0.250–3.680 0.004 0.950
32 rs6532039 3496 Intron 3 A/G 54/32 68/40 1.007 0.561–1.811 0.001 0.980
33 novel.6 4084 Intron 3 C/T 86/04 107/01 4.977 0.546–45.351 2.469 0.116
37 rs7695531 5014 Intron 5 A/G 87/03 105/03 1.207 0.238–6.131 0.052 0.820
38 rs6532040 5332 Intron 5 A/G 87/03 105/03 1.207 0.238–6.131 0.052 0.820
40 rs6811536 5535 Intron 5 C/T 87/03 105/03 1.207 0.238–6.131 0.052 0.820
44 rs4754 5822 Exon 6 C/T 60/30 68/40 0.850 0.473–1.529 0.295 0.587
47 rs10516799 6320 Intron 6 C/G 87/03 105/03 1.207 0.238–6.131 0.052 0.820
51 rs1126616 6982 Exon 7 T/C 60/30 68/40 0.850 0.473–1.529 0.295 0.587
54 rs1126772 7315 Exon 7 A/G 53/37 66/42 1.097 0.620–1.942 0.101 0.751
56 rs9138 7471 Exon 7 C/A 59/31 68/40 0.893 0.498–1.602 0.143 0.705
CI, confidence interval; htSNP, haplotype-tagging single nucleotide polymorphism; OR, odds ratio; SNP, single nucleotide polymorphism.
The boldface represents htSNPs. P values were calculated using the w2 test.
** Po0.01.
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performed in 126 cases and 214 controls, and the association
was validated. The G allele carrier for novel 2 or T-allele
carrier for novel 3 had a 1.6- (OR¼ 1.642, 95% CI: 1.058–
2.549) or 1.8-fold (OR¼ 1.762, 95% CI: 1.132–2.743)
increased kidney stone risk compared with those of the
T-allele carrier for novel 2 or G-allele carrier for novel 3
(Table 3). In block 2, the haplotype G-T-T-G carrier had
a remarkably higher (OR¼ 1.676, 95% CI: 1.072–2.621) and
rs
27
28
12
7
rs
28
53
74
4
rs
11
72
86
97
rs
68
39
52
4
rs
68
40
36
2
rs
65
32
03
9
rs
76
95
53
1
rs
65
32
04
0
rs
68
11
53
6
rs
10
51
67
99
rs
11
26
61
6
rs
11
26
77
2
rs
47
54
rs
91
38
rs
11
73
05
82
rs
28
53
74
9
rs
28
53
75
0
n
o
ve
l
n
o
ve
l.2
n
o
ve
l.3
n
o
ve
l.4
n
o
ve
l.5
n
o
ve
l.6
Block 1 (1 kb) Block 2 (1 kb) Block 3 (0 kb) Block 4 (3 kb)
2 4 5 7 10 11 19 20 22 25 26 27 29 32 33 37 38 40 44 47 51 54 56
Figure 1 | Pair-wise LD and haplotype block structure in the OPN gene from 99 study subjects. The degree of LD was evaluated between
any two SNPs with rare allele frequenciesX1%. The white bar indicates the approximate span of the OPN gene. The corresponding number of
the SNP is displayed in the upper triangle. The upper four pentagons represent the haplotype blocks and the boldfaced SNPs in the blocks
represent htSNPs. Bottom left panels display the frequency of haplotype and levels of recombination between the blocks. The level of LD is
indicated with the color scheme (bottom right).
Table 2 | Association analysis of haplotypes in four LD blocks between 45 cases and 54 controls
Frequency of haplotype
Block Haplotype Frequency Cases (n=45) Controls (n=54) OR 95% CI v2 P-Value
Block 1 SNP2-4
AG 0.808 0.833 0.787 1.3529 0.658–2.782 0.678 0.4101
GT 0.192 0.167 0.213 0.7391 0.360–1.520 0.678 0.4101
Block 2 SNP10-11-19-20
TGCA 0.793 0.833 0.759 1.5854 0.781–3.220 1.641 0.2003
TGTG 0.101 0.011 0.176 0.0526 0.007–0.402 14.685 0.0001**
GTTG 0.096 0.156 0.046 3.7947 1.310–10.989 6.755 0.0093**
TGTA 0.01 0.000 0.019 — — 1.684 0.1944
Block 3 SNP25-26
TA 0.732 0.722 0.741 0.91 0.484–1.710 0.086 0.7695
AT 0.232 0.222 0.241 0.9011 0.464–1.751 0.094 0.7587
TT 0.035 0.056 0.019 3.1176 0.590–16.471 1.975 0.1600
Block 4 SNP32-44-51
ACT 0.631 0.632 0.630 0.9689 0.544–1.727 0.001 0.9692
GTC 0.348 0.322 0.370 0.8082 0.448–1.458 0.501 0.4792
GCT 0.016 0.034 0.000 — — 3.75 0.0528
CI, confidence interval; LD, linkage disequilibrium; OR, odds ratio.
P-values were calculated using a w2 test or Fisher’s exact test.
**Po0.01.
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the haplotype T-G-T-G carrier had a remarkably lower
(OR¼ 0.351, 95% CI: 0.179–0.689) risk of developing
nephrolithiasis compared with other haplotypes (Table 4).
A case-only analysis was performed among nephrolithiasis
patients. No significant association was found between SNPs
or haplotypes and clinical characteristics, such as gender
difference, familial history of stone disease, biochemistry of
the urine, primary age of first incidence, stone number, stone
frequency, and stone component (data not shown). We also
searched transcription factor-binding sites of the promoter
region of the OPN gene. However, there was no transcription
factor within the sites SNP10 or SNP11.
DISCUSSION
There is growing evidence that macromolecular proteins
may play important modulating roles in the development of
nephrolithiasis. We are in the process of comprehensively
evaluating the possible associations between sequence
variants of these proteins and kidney stone risk. OPN is a
remarkable multifunctional molecule involved in diverse
biological processes, including inflammation, cell survival,
and immune responses.17 It is also a central player in
modulating and interacting with crystals. In this study, we
resequenced the entire 11 kb OPN gene, including all exons,
introns, an approximately 2100 bp promoter and 30-untrans-
lated region using 99 DNA samples. This strategy allowed us
to discover previously unreported polymorphisms and per-
form a faithworthy LD and haplotype structure analysis. We
genotyped 61 polymorphisms in the OPN gene and six novel
polymorphisms were identified. Two novel SNPs (novel 2 and
novel 3) located in the promoter region of the OPN gene
were significantly associated with kidney stone risk (P¼
0.026 and 0.0113, respectively). Two haplotypes, a reduced
risk-associated haplotype (T-G-T-G) and an increased
risk-associated haplotype (G-T-T-G), were detected to be
remarkably associated with nephrolithiasis (P¼ 0.023 and
0.0016, respectively). These findings suggest that the OPN
gene is dually associated with the risk of nephrolithiasis and
may have a different function in crystal formation during the
development of nephrolithiasis.
Since our discovery of the OPN protein from the urinary
stone matrix in 1992,2,9 the controversial question of whether
OPN inhibits or promotes kidney-stone formation has been
debated continuously in recent years. Many groups have
characterized its unique expression profile, but few have
searched for variants associated with kidney stone risk. Here,
we identified two distinct haplotypes associated with nephro-
lithiasis. Different association of genetic variation with
disease had already been reported in other study on DLG5
gene and inflammatory bowel disease.18 To our knowledge,
our finding is the first direct genetic evidence that OPN can
increase or reduce the risk of stone formation and provides a
potential genetic clue to clarify this question in the future.
A recent study showed that Randall’s plaques, initially
formed in the basement membrane of the thin limbs of the
loop of Henle, extended to the vasa recta and interstitial
tissue and finally to the papillae.19 In these processes, crystal
particles may stimulate an array of responses, inducing
localized injury and tubulointerstitial inflammatory reac-
tions,20 and macrophages are induced to release inflamma-
tory cytokines, such as tumor necrosis factor-a and
interleukin-6, and remove crystal deposits from the renal
interstitium.21 The OPN protein was observed to locate in
cells of the loops of Henle and collecting ducts as well as on
sites of plaque, mainly on the surfaces of the apatite crystal
phase and at the junction of the crystal/organic layers.22
Crystals and oxalate ions may be involved in the upregulation
of OPN in renal fibroblasts.23 As a multifunctional protein,
OPN is involved in the inflammatory process24 and the
initiation of cell-mediated immune reactions,25 regulation of
inducible nitric oxide synthase in both macrophages and
renal tubular epithelial cells,26,27 protection of renal epithelial
Table 3 | Association analysis of htSNPs in LD block 2 between 126 cases and 214 controls
Block 2 Alleles Cases Controls
htSNPs Major/minor (n=126) (n=214) OR 95% CI v2 P-value
SNP10 T/G 203/45 363/49 1.642 1.058–2.549 4.954 0.026*
SNP11 G/T 207/45 381/47 1.762 1.132–2.743 6.41 0.0113*
SNP19 C/T 197/55 328/100 0.982 0.681–1.418 0.213 0.644
SNP20 A/G 193/59 328/100 1.003 0.694–1.448 0 0.9886
CI, confidence interval; htSNP, haplotype-tagging single nucleotide polymorphism; OR, odds ratio; SNP, single nucleotide polymorphism.
*Po0.05.
Table 4 | Association analysis of haplotypes in LD block 2 between 126 cases and 214 controls
Block 2 (SNP10–20) Haplotypes Cases Controls
frequency (n=126) (n=214) OR 95% CI v2 P-value
TGCA 0.756 192.0/60.0 321.9/106.1 1.055 0.659–1.364 0.08 0.7777
GTTG 0.132 43.0/209.0 46.8/381.2 1.676 1.072–2.621 5.189 0.0227*
TGTG 0.088 11.0/241.0 49.2/378.8 0.351 0.179–0.689 9.978 0.0016**
TGCG 0.012 4.0/248.0 3.8/424.2 1.801 0.438–7.395 0.667 0.414
CI, confidence interval; LD, linkage disequilibrium; OR, odds ratio.
*Po0.05. **Po0.01.
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cells from apoptosis,28 and modulation of macrophage
adhesion,29,30 migration,29,30 and cytokine release.31 OPN is
also associated with tissue repair and fibrosis.32 The exact
molecular mechanism by which OPN exerts its various effects
in stone formation remains unclear. In addition, as a member
of the SIBLING family, OPN was also reported to be
coexpressed in the renal distal tubules along with its partner
matrix metalloproteinase-3 in monkey kidney.33 Interactions
between OPN and matrix metalloproteinase-3 in the
development of stone formation remain unclear. The fact
that OPN knockout mice do not spontaneously develop
crystal deposition indicates that other urinary macro-
molecular proteins can adequately compensate for the
absence of OPN.34 These observations may also add to the
complexity of the stone-formation process. Definitive data
regarding the role of OPN were lacking until recently.
Mo et al. reported that OPN was markedly induced in
renal epithelial cells of Tamm–Horsfall protein-knockout
mice and was moderately induced in wild-type mice under
high calcium/oxalate conditions.5 This finding suggests
that OPN and Tamm–Horsfall protein may function together
to keep renal stones from forming. The finding35,36 that
the concentration of OPN was lower in stone formers than
those in healthy controls suggests that low levels of OPN
may provide limited inhibition of crystallization. Our finding
suggests, on a genetic level, that there might be different
unknown pathogenesis between individuals with reduced
risk-associated OPN haplotype and individuals with increased
risk-associated OPN haplotype. Whether individuals with
different haplotypes, under certain conditions, tend to express
different OPN–protein concentrations remains unclear. These
definite conclusions will be validated by a larger number of
studies in the future.
The SIBLING family is characterized by similarities in
gene structure, location as a cluster on the same chromosome
4 in humans, and expression in mineralized tissues.37
Whether there exists high genetic LD among these genes
remains unclear. Recently, other members of the SIBLING
family, such as bone sialoprotein, dentin matrix protein-1,
dentin sialophosphoprotein, and matrix extracellular phos-
phoglycoprotein, had also been observed to express or
coexpress with its partner in normal monkey kidney tissue.33
However, there has not been a study of the association
between stone formation and the SIBLING gene family.
In this study, we only focused on OPN as a candidate
gene because of its unclear role in stone formation.
Additional studies of genetic linkage of the SIBLING family
will further clarify interactions among these genes in the
process of stone formation.
In this study, several characteristics and limitations should
be mentioned. First, our study individuals all came from the
Asian Japanese ethnic group. This eliminated the possibility
of confounding owing to population stratification. On the
other hand, it also limited the ability to perform cross-popu-
lation comparisons. In addition, the fact that the incidence of
nephrolithiasis in Japan (about 3.8–9%)38 is lower than that
in Europe and North America (about 8–15%)1 may not only
reflect a difference in dietary habits including fluid intake,
calcium and oxalate metabolism, and dietary fat intake, but
also imply the possibility of distinct genetic polymorphism
distributions in different ethnic groups. Second, an entire
resequencing containing the non-coding region brought us
unabridged variant information in OPN gene and provided
us with a reliable analysis of the LD characteristics and
haplotype block structure. Therefore, we believe that these
findings represent true association in the Japanese ethnic
group.
In summary, our study showed a dual association between
OPN sequence variants and kidney stone risk and presents a
potential genetic clue towards the role of OPN in nephro-
lithiasis.
MATERIALS AND METHODS
Study subjects
Our study group consisted of a total of 126 unrelated Japanese
patients (mean age7s.d.¼ 57.6713.5 years) with nephrolithiasis,
who underwent treatment at Nagoya City University Hospital from
2000 to 2006. The clinical characteristics of all of the patients are
listed in Table 5. Blood and 24-h urine were collected after the
patient’s symptoms were ameliorated. Urine calcium, oxalate, and
Table 5 | Characteristics of 126 kidney stone cases
Characteristics Cases (n) %
Sex
Male 93 73.8
Female 33 26.2
Primary age
o=55 years 83 65.9
455 years 43 34.1
Familial history
Yes 9 7.2
No 117 92.8
Urine calcium excretiona
Hypercalciuric 21 16.7
Normocalciuric 105 83.3
Urine oxalate excretion (180–350mmol)
Hyperoxaluria 33 26.2
Normoxaluria 93 73.8
Urine citrate excretion (2.4–5.1 mmol)
Hypocitraturia 18 14.3
Normocitraturia 108 85.7
Stone number
Multiple 87 69.0
Single 39 31.0
Stone frequency
Primary 31 24.6
Recurrence 95 75.4
Stone component
CaOx (450%) 107 84.9
CaP (450%) 19 15.1
ao7.5 mmol in male, o6.3 mmol in female, or o0.1 mmol/kg.
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citrate were measured. Patients were diagnosed as hypercalciuric
when 24-h urinary calcium excretion was greater than 7.5 mmol in
male patients or 6.3 mmol in female patients or greater than
0.1 mmol/kg of body weight under a normal diet. Patients were
considered hyperoxaluria when 24-h urinary oxalate excretion was
greater than 350mmol and were considered hypocitraturic when
24-h urinary citrate excretion was lower than 2.4 mmol under a
normal diet. The number of stones was confirmed by X-ray before
treatment. The stone composition was analyzed by infrared
spectroscopy. Considering the complex etiology and different
pathogenesis, we rigorously eliminated cases of hyperparathyroidism
by measurement of serum parathyroid hormone level (454 pg/ml)
and serum calcium level corrected for serum albumin and
eliminated cases of infected stone largely composed of magnesium
ammonium phosphate (MgNH4PO4 6H2O) and other non-
calcium-salt stones, such as cystine stones and uric-acid stones by
stone composition analyses.
The control group consisted of 214 aged Japanese subjects (mean
age7s.d.¼ 68.6711.8 years, 165 males and 49 females) without a
history of nephrolithiasis or a family history of stone disease. All of
these control subjects were given a general medical inquiry and
partly confirmed with X-ray and routine blood and urine assays. All
of the patients and controls were recruited from the same racial,
ethnic, and the same geographical and environment stratification.
The protocol was previously approved by the Institutional Review
Boards and the appropriate informed consent was obtained from all
patients and control subjects in this study. Genomic DNA from
patients and controls was extracted from peripheral blood using a
QIAamp Blood kit (Qiagen, Hilden, Germany).
Long-range PCR amplification
The human OPN gene maps to the chromosome 4 (4q13), spans
about 11 kb and contains seven exons.39 A long-range polymerase
chain reaction (PCR) spanning the entire OPN gene sequence was
performed on genomic DNA samples from 126 patients and 214
controls, using the platinum Taq DNA polymerase high-fidelity kit
(Invitrogen, Carlsbad, CA, USA), which possesses a proofreading
ability to rule out errors that may occur during the long-range
amplification. Briefly, according to the manufacturer’s guidelines,
300 ng of genomic DNA was used as a template in 50 ml reactions.
Specific amplification primers were designed from published
sequences of human OPN (GenBank accession no. D14813) and
are listed in Table 6. The final concentrations of reagents included
2 mM MgSO4, 0.2 mM deoxynucleoside triphosphate, and 0.2 mM of
each primer, 2.5 U high-fidelity platinum Taq DNA polymerase and
10-fold diluted high-fidelity PCR buffer. PCR amplification was
performed with one cycle at 941C for 30 s and 35 cycles at 941C for
30 s, 551C for 30 s and 681C for 11 min. Products were resolved on
1% agarose gels and purified with GFX PCR DNA and a gel band
purification kit (Amersham Biosciences, Poole, UK).
Genotyping
The OPN gene was entirely resequenced with cycle-sequencing PCR
amplifications in 45 kidney stone cases and 54 controls. Twenty-five
walking primers were designed to cover the entire OPN gene using
the Primer Premier 5.0 program (Table 6). PCR reactions were
performed using the Applied Biosystems (ABI; Foster City, CA,
USA) BigDye terminator cycle sequencing ready reaction kit
(Applied Biosystems) according to the manufacturer’s guidelines.
Purified long-range PCR products (50 ng) were used in each cycle-
sequencing PCR reaction. The cycle-sequencing parameters were
25 cycles of 951C for 15 s, 551C for 15 s and 601C for 4 min. Reaction
products were precipitated with ethanol, resuspended in form-
amide-loading buffer, and electrophoresed on an ABI 3100 auto-
mated DNA sequencer (Applied Biosystems). Sequences were
aligned to compare with the published genomic sequences
(GenBank accession no. D14813) among all individuals and SNPs
were validated using SeqScape V2.1 if the second mixed bases were
X45% of the highest peak. Four htSNPs were further genotyped
in the additional 81 nephrolithiasis cases and 160 controls. Of
them, two novel htSNPs, SNP10 and SNP11, were genotyped by
direct sequencing, and two htSNPs, rs2853749 and rs2853750, were
genotyped by a fluorescent 50endonuclease assay using an ABI Prism
7700 sequence-detection system, with the recommended protocols.
Primers and probes were designed by Assays-by-Design (order
no. 185315362, Applied Biosystems). In brief, real-time PCR was
performed in a total volume of 25 ml, containing 10–20 ng of
genomic DNA, 12.5 ml of 2TaqMan universal PCR master mix,
200 nM of forward primer, 200 nM of reverse primer, and 250 nM of
TaqMan probe. The amplification reaction was carried out with one
cycle at 951C for 10 min and 40 cycles at 921C for 15 s, and 601C
for 1 min.
Statistical analysis
The Hardy–Weinberg equilibrium test was done for each poly-
morphism. The Haploview software package (http://www.broad.
mit.edu/mpg/haploview/about.php) was used to estimate the pair-
wise LD and haplotype blocks structure and identify htSNPs using
the CI algorithm.40 The allele distribution of haplotypes and each
Table 6 | Primers used for long PCR amplification and cycle
sequence PCR in the OPN gene
Position Primer
Long PCR 2384 Forward 50-ACCTCCCCGATAGTCAGAAT-30
9557 Reverse 50-AACTTGGTCATGCCCTTGGAT-30
Sequence PCR
1 2304 Forward 50-TCAACTCCAAAGCATCCCAGAC-30
2 1954 Forward 50-CTTTTTTCAGAAATGCTGCC-30
3 1506 Forward 50-AATGTTCATGAAACCTATG-30
4 1066 Forward 50-CTTTACATACCTTGGGAG-30
5 614 Forward 50-CTCTCAGTCAGAAACTGC-30
6 131 Forward 50-AACCAGAGGGGGAAG TGTGG-30
7 291 Forward 50-ACTTAAAAATACTTCCACTGG-30
8 739 Forward 50-GTACATGTTGGAAAAATGG-30
9 1180 Forward 50-CACTACCATGAGAATTGC-30
10 1623 Forward 50-TATGATGAGTTATCGCATG-30
11 2051 Forward 50-GTTCAATTCCAGTTGAACAG-30
12 2476 Forward 50-GTTAGGATTACTGGGTGGT-30
13 2938 Forward 50-CTGGGATTACAGGCGTAGC-30
14 3387 Forward 50-CATATGGCTATTGAGCACTC-30
15 3834 Forward 50-CTTCTTGTTCCATGGACTG-30
16 4269 Forward 50-TTTTTCCATTCATCCCTAC-30
17 4711 Forward 50-ACAAGAGGTAAGTTCTCAT-30
18 5172 Forward 50-AGCAAGTTAGATAAATTACC-30
19 5623 Forward 50-GCCATGGTATGTACTGTG-30
20 6064 Forward 50-GCAGACCTGACATCCAGG-30
21 6494 Forward 50-CTAACAATTCACTTCCTCT-30
22 6943 Forward 50-CCACAGCCACAAGCAGTC-30
23 7385 Forward 50-TGTCTATGTTCATTCTATAG-30
24 7834 Forward 50-CTTGTCATTTATTTGTGCTG-30
25 8294 Forward 50-TGGGCACAAATCTGAATAG-30
PCR, polymerase chain reaction.
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SNP with a minor allele frequency greater than 1% were assessed
using w2 test or Fisher’s exact test between the case and control
samples. OR and 95% CI were calculated to determine the risk of
kidney stone associated with a given OPN allele. Transcription
factor-binding sites of the promoter region of OPN gene were
searched using the TFSEARCH program (http://www.cbrc.jp/
research/db/TFSEARCH.html) and NCBI database (http://www.
ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=506341). Stati-
stical analysis was performed using the statistical package for social
sciences (version 10.0; SPSS Inc., Chicago, IL, USA). Pp0.05 was
considered as significant.
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